Clene Inc. (CLNN) Tops Q3 Earnings Estimates
Clene Inc CLNN
$4.55
▲ +3.88%
(+$0.17)
🎈 Low Float
Open
$4.41
Prev Close
$4.38
Day Range
$4.40 – $4.85
52W Range
$3.02 – $11.23
Market Cap
$63.07M
Beta
1.15
EPS (TTM)
$-3.49
📋 Company Profile
| Industry | Biotechnology |
| Country | US |
| Exchange | NASDAQ NMS - GLOBAL MARKET |
| Currency | USD |
| IPO Date | 2018-08-27 |
| Shares Out. | 14,210,000 |
| Website | clene.com/ ↗ |
| Phone | 18003464646 |
| Employees | 79 |
| Revenue | $56,000 |
| Gross Profit | $40,000 |
| Net Income | $3.9M |
| Free Cash Flow | -$16.6M |
| Total Assets | $22.2M |
| Total Liabilities | $37.0M |
| Equity | -$14.8M |
About Clene Inc
Clene Inc is a clinical-stage pharmaceutical company pioneering the discovery, development, and commercialization of novel clean-surfaced nanotechnology (CSN) therapeutics. It is focused on the development of therapeutics for neurodegenerative diseases. It developed an electro-crystal-chemistry drug development platform that enables the production of concentrated, stable, clean-surfaced nanocrystal suspensions. It operates in one segment the development and commercialization of dietary supplements (Supplements). Products includes CNM-Au8, CNM-ZnA, CNM-AgZn17, rMetx, KHC46.
Clene Inc is a publicly traded company under the ticker symbol CLNN on the NASDAQ NMS - GLOBAL MARKET, operating in the Biotechnology industry. Quotes and metrics shown here are sourced from public market data and refreshed regularly.
📊 Analyst Ratings
11 analysts (2026-11-01)